1. Home
  2. REFI vs NKTX Comparison

REFI vs NKTX Comparison

Compare REFI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Atlantic Real Estate Finance Inc.

REFI

Chicago Atlantic Real Estate Finance Inc.

HOLD

Current Price

$10.17

Market Cap

241.1M

Sector

Real Estate

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.27

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REFI
NKTX
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.1M
198.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
REFI
NKTX
Price
$10.17
$2.27
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
179.8K
790.6K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
15.79%
N/A
EPS Growth
N/A
11.88
EPS
0.23
N/A
Revenue
$48,857,628.00
N/A
Revenue This Year
$17.47
N/A
Revenue Next Year
$0.06
N/A
P/E Ratio
$43.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.02
$1.70
52 Week High
$14.57
$3.72

Technical Indicators

Market Signals
Indicator
REFI
NKTX
Relative Strength Index (RSI) 33.89 34.58
Support Level N/A $1.84
Resistance Level $12.41 $2.32
Average True Range (ATR) 0.19 0.24
MACD -0.05 -0.08
Stochastic Oscillator 16.30 4.36

Price Performance

Historical Comparison
REFI
NKTX

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: